Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Bioxyne Limited ( (AU:BXN) ) has shared an update.
Bioxyne Limited has released its first quarter results for FY2025, highlighting its continued focus on innovative health and wellness products. The company’s subsidiary, Breathe Life Sciences, has expanded its operations internationally, solidifying its position as a leader in the manufacturing and distribution of therapeutic goods, including cannabis-based products. This expansion is expected to enhance Bioxyne’s market presence and offer significant growth opportunities in the pharmaceutical and consumer health sectors.
More about Bioxyne Limited
Bioxyne Limited is an Australian pharmaceutical company that focuses on developing and commercializing innovative medicines and active pharmaceutical ingredients. Its subsidiary, Breathe Life Sciences (BLS), operates internationally, manufacturing and distributing controlled substances like medicinal cannabis, Psilocybin, and MDMA. BLS is a market leader in Australia and engages in pharmaceuticals, medical cannabis, consumer health products, and novel foods across the UK, Europe, and Japan.
Average Trading Volume: 4,315,905
Technical Sentiment Signal: Buy
Current Market Cap: A$89.78M
For an in-depth examination of BXN stock, go to TipRanks’ Overview page.